

Basic-report update

Analyst

Dr. Roger Becker, CEFA
 +49 69 71 91 838-46
 roger.becker@bankm.de

Evaluation result

BUY

(previously BUY)

Fair value

€ 29.33

(previously € 28.22)

H1/2010 - Profitability further increasing

- Total revenues during H1 stable at €52.9 Mill. (+1%, YoY)
- Operating result at €10 Mill., up 28% compared to previous year
- EBIT margin gained 3.9%-age points due to a bias in sales of high margin oil-drill bits in Q1 and the realization of synergies
- Net result after minorities: +29.4%; net margin up 2.1%-age points
- Liquid funds at period end at €29 Mill.
- Management reiterates €1.80 earnings per share for Fiscal Year 2010
- Dividend payment for 2009: €0.45 per share
- We adjust our earnings forecast upwards

During the first half 2010, Eckert & Ziegler AG (EZAG) has booked revenues amounting to €53 Mill. translating into a result of €5.1 Mill. after minorities (+29.4%, yoy). By this means, the expectations in the context of our quarterly forecast (€52.5 Mill./€4.4 Mill.) were visibly exceeded.

Compared to previous year, EBIT margin increased by 3.9%-age points, which is largely due to synergies resulting from the integration of Nuclitec as well as from remarkable sales of high-margin oil-drill bits in Q1. The cutback of minorities from 59% to 28%, a result of the IBt mandatory takeover bid, significantly contributed to the improvement of net result growth and margin.

Compared to year end balance sheet, liquid funds came down by €14.5 Mill. to €29.2 Mill. (as of June 30). By yoy comparison, operating cash-flow came down by 14% to €5.6 Mill. owing to a capital-absorbing increase in net working capital by €4.1 Mill. Investment activities are characterized by the pay-out of €22.5 Mill. for the acquisition of additional IBt shares (see above). Investments in fixed assets are within operative scope at €2.4 Mill. During H1, €8.25 Mill. were raised for partial financing of the IBt shares; at the same time, €2.5 Mill. of debt were redeemed.

The consistent advancement of profitability prompts us to re-evaluate the stock; based on the analysis of free cash flows and of market comparables, we calculate a fair value of €29.33 per share. We reiterate our "Buy" rating.

Key data / Earnings

Year	Sales (mln €)	EBITDA (mln €)	EBIT (mln €)	EBT (mln €)	adj. net (mln €)	adj. EPS (€)	DPS (€)	EBIT- Margin	Net- Margin
2009	101.4	27.9	16.4	15.2	7.5	1.97	0.30	16.2%	7.4%
2010e	108.1	24.4	18.4	17.2	9.7	1.85	0.44	17.1%	9.0%
2011e	116.9	25.8	19.4	17.5	11.0	2.09	0.59	16.6%	9.4%
2012e	126.2	29.8	22.8	20.9	13.2	2.51	0.63	18.1%	10.5%
2013e	135.0	33.9	26.4	24.4	15.6	2.96	0.75	19.6%	11.5%

Source: BankM Research

Sector	Medical Technology
WKN	565970
ISIN	DE0005659700
Bloomberg/Reuters	EUZ GY Equity
Accounting standard	IFRS
Financial year	Dec 31
Financial report Q3	Nov 2, 2010
Market segment	Regulated Market
Transparency standard	Prime Standard

Financial ratios

	2010e	2011e	2012e
EV/Sales	1.6	1.5	1.4
EV/EBITDA	7.0	6.6	5.7
EV/EBIT	9.2	8.8	7.5
P/E adj.	13.5	12.0	10.0
Price/Bookvalue	2.0	1.8	1.6
Price/FCF	-1.5	4.2	3.1
ROE	14.6	16.9	18.2
Dividend yield	1.8	2.4	2.5

Number shares

(million) 5.260

Market cap / EV

(million €) 131.5/ 170.4

Free float

64.2%

Ø daily trading vol.

(3M, in T€) 268.4

12 months high/low

(XETRA-close) € 26.24/15.50

Price Aug 4, 2010

(XETRA-close) 25.00 €

Performance

absolute 1M 6M 12M

relative -0.3% 0.6% -14.9%

Benchmark index

MEDTECH PERFORM.



Eckert & Ziegler AG (blue/black), Performance 1 year vs. DAX Subsector MedTech (red/grey)

Source: Deutsche Börse AG

PLEASE CONSIDER IMPORTANT INFORMATION, DISCLOSURES AND THE DISCLAIMER AT THE END OF THIS DOCUMENT!

This document has been prepared due to a service agreement with the respective issuer. BankM – Repräsentanz der biw AG is the designated sponsor of the company's stock and in this function as a designated sponsor, regularly holds a trading stock or long or short positions in the company's stock. Equity investments generally involve high risks. Potential investors should take into account that share prices may fall and rise and that income from an investment may fluctuate considerably. Investors may lose some or all of the money invested. Investors make their decisions at their own risk.

Segment Discussion

Main sales driver, again, was the segment "Industry" - now being renamed as "Isotope Products" - with 48.1% of total sales, followed by the segments "Therapy" (27.9%) and "Radiopharmacy" (18.9%). The business division "Environmental Services", formerly being integrated within the Industry segment and since the beginning of FY 2010 operating as a separate segment, contributed 5.0% to total sales.

The Industry segment benefitted from a remarkably strong business in high margin oil-drill bits as well as from synergies resulting from the successful integration of Nuclitec. As previously announced by management, sales of oil-drill bits did not remain on the same level as in Q1; while the segments' revenues - by yoy comparison - decreased by 3.2%, operating profitability significantly increased by 10%-age points.

The "Therapy" segment, likewise, reports decreasing sales (-9.5%); however, comparability is strongly limited, given the retrospective out-booking of Q2/2009 revenues in the context of the Russian Joint Venture and their reclassification as prepayments on the balance sheet.

Accompanied by a margin improvement of 4%-age points, sales within the segment "Radiopharmacy" increased by almost 3%. The market launch of the Gallium generator is scheduled for Q3 or Q4/2010; a substantial contribution is to be expected not before 2011.

The new segment "Environmental Services" was slightly in deficit owing to expenditures for the preparation of new business. Regarding this segment, management anticipates 2010 revenues amounting to €5 Mill., resulting from the already existing business.

Current Developments

- Gain of a major order in France for the supply of small permanent implants (seeds) for prostate cancer treatment to specialized hospitals for the next three years
- IBt publishes first results regarding the utilization of permanent implants for monotherapy of early breast cancer; further, a first brain tumor patient was treated with seeds
- EZAG is selected as main supplier for the radioactive component of leukemia drug ZEVALIN[®], being marketed by the US-based drug company Spectrum Pharmaceuticals, Inc.
- The development freeze ("Veränderungssperre") imposed on industrial estate "Thune" (district of Braunschweig) has been cancelled. As a result, EZAG's fully owned subsidiary "Kompetenzzentrum für sichere Entsorgung, GmbH (KSE; Competence Center for Safe Waste Disposal)", which is operating the group's segment "Environmental Services", is now formally able to proceed with its project of conditioning weak to mid radioactive waste originating from the "Schachtanlage Asse" (a shut down mine shaft near Wolfenbüttel, Germany). Still, this subject remains a political issue; we will observe the progress of the discussion

Stock and Valuation

Year-to-date, EZAG's stock has gained 39.7%, increasing from €17.90 to €25.00 (XETRA close August 4, 2010). During the same period, the benchmark (Daxsubsec. Medical Technology Performance) has gained 27.7%, only. Since our last update from May 10, 2010, the share price increased by 28.2%, significantly out-performing the benchmark (+10.9%).

Based on daily stock price returns since beginning of the year, the annualized volatility is at 42.5% with a mean daily trading volume of ca. 15.600 pieces and a maximum of 151,000 pieces. During the reference period H1/2009, volatility was at 66% with a mean daily trading volume of ca. 5,700 pieces and a maximum of 46,000.

On the basis of the company's H1 reporting and the consistently advancing profitability, we have adjusted our earnings forecasts upwards and present an updated detailed planning for Fiscal Year 2010.

Our DCF analysis now returns an equity value of €146.9 Mill. (previous: €145.2 Mill.) translating into a price of €27.92 per share (previous: 27.61). Our peer group analysis - based on the P/E ratio for 2010 - suggests a price of €30.74 per share (previous: €28.83). Equally weighted, we calculate a fair value of €29.33 per share (previous: €28.22).

Considering both, the results of our fundamental analysis in tandem with a current P/E ratio of 13.4, EZAG's stock is currently favorably valued; therefore, we continue to recommend buying the stock.

DCF Model

DCF analysis based on future free cash-flows 2009-2017 + Terminal Value

in T€		Forecast										Terminal Value 2018+
		2009a	2010e	Phase 1		Phase 2		Phase 2		2017e		
		Basis	0.5	1.5	2.5	3.5	4.5	5.5	6.5	7.5		
	Growth	42%	7%	8%	8%	7%	6%	6%	5%	4%	1%	
	Revenues	101,399.0	108,066.2	116,850.1	126,161.2	134,992.4	143,092.0	151,677.5	159,261.4	165,631.8		
	EBIT	16,418.0	18,430.7	19,383.9	22,820.9	26,443.3	28,029.9	29,711.7	31,197.3	32,445.2		
	- Tax	-2,627.0	5,529.2	5,815.2	6,846.3	7,933.0	8,409.0	8,913.5	9,359.2	9,733.5		
	+ Depreciation	11,525.0	5,943.6	6,426.8	6,938.9	7,424.6	7,870.1	8,342.3	8,759.4	9,109.8		
	+ change in long-term provisions	-6,821.0	-1,000.0	-1,000.0	-1,000.0	-1,000.0	-1,000.0	-1,000.0	-1,000.0	-1,000.0		
	- changes in net working capital	-6,534.0	3,529.8	4,107.2	4,398.9	1,990.8	1,825.8	1,935.4	1,709.6	1,436.1		
	- other non-cash items	11,018.0	-1,574.4	-1,731.9	-1,905.1	-2,095.6	-2,535.6	-1,175.4	0.0	0.0		
	- Capex	9,698.0	30,945.3	9,348.0	10,092.9	10,799.4	11,447.4	12,134.2	12,740.9	13,250.5		
	= Free Cash Flow	9,567.0	-15,055.6	7,272.1	9,326.7	14,240.3	15,753.4	15,246.3	15,147.0	16,134.8	16,296.1	
	Terminal Value										221,462.5	
	Discount factor		0.96	0.89	0.82	0.76	0.70	0.64	0.59	0.55		
	NPVs of Free Cash Flows	n.a.	-14,465.9	6,450.8	7,637.9	10,766.2	10,995.6	9,824.4	9,010.9	8,861.4		
	NPV of Terminal Value										121,291.6	
	Valuation	Proportion of TV										
	Result of Future Cash Flows	49,081.2	29%									
	+ Result of Terminal Value	121,291.6	71%									
	= Value of the Entity	170,372.8										
	+ Cash (30.06.2010)	29,161.0										
	- LT Debt (30.06.2010)	47,208.0										
	- Minorities (30.06.2010)	5,463.0										
	Value of Equity	146,862.8										
	Price per Share	27.92										

Source: BankM Research

Sensitivity Analysis of Terminal Value (TV)

Key Model Assumptions

Riskfree Return	3.30%
Current Yield (D)	
Market Beta (relevered, adj. for target Capital Structure)	0.99
Beta im Terminal Value = 1	
Market Return	10.00%
Cost of Equity	9.93%
Target weight	60%
Cost of Debt	8.00%
Target weight	40%
Tax shield	26.3%
WACC	8.32%
Growth Rate Terminal Value	1.00%
WACC TV	8.36%

Discount rate of TV

Growth Terminal Value		Discount rate of TV						
		6%	7%	8%	8.36%	9%	10%	11%
0.25%		34.15	29.81	26.59	25.63	24.11	22.14	20.53
0.50%		35.56	30.84	27.37	26.35	24.72	22.63	20.94
0.75%		37.10	31.94	28.21	27.11	25.38	23.16	21.37
1.00%		38.80	33.14	29.10	27.92	26.07	23.71	21.83
1.25%		40.67	34.44	30.06	28.79	26.81	24.30	22.31
1.50%		42.75	35.86	31.10	29.72	27.60	24.92	22.81
1.75%		45.08	37.42	32.21	30.73	28.44	25.58	23.34

Source: BankM Research

BITTE BEACHTEN SIE DIE HINWEISE, ANGABEN UND DEN DISCLAIMER AM ENDE DIESER STUDIE!

Peer Group Comparison

Company	Price	MarketCap (Mio.)	EPS			P/E		
			2009a	2010	2011	2009a	2010	2011
aap Implantate AG	1.25	34.85	0.07	0.01	0.02	17.9	125.0	62.5
Biolitec AG	3.65	38.17	0.06	0.22	0.36	60.8	16.6	10.1
Carl Zeiss Meditec AG	11.93	970.02	0.62	0.64	0.72	19.2	18.6	16.6
IBt - International Brachytherapy S.A.	2.80	49.15	0.27	0.22	0.24	10.4	12.7	11.7
Pulsion Medical Systems AG	3.27	31.32	0.05	0.24	0.26	65.4	13.6	12.6
Stratec Biomedical Systems AG	29.12	334.36	1.02	1.37	1.70	28.5	21.3	17.1
UMS Medical Syst. Intl AG	6.95	37.85	0.48	0.62	0.66	14.5	11.2	10.5
W.O.M. World of Medicine AG	10.63	97.20	0.10	0.00	n.a.	106.3	n.a.	n.a.
Median		43.66	0.12	0.24	0.36	23.9	16.6	12.6
Eckert & Ziegler AG	24.88	130.88	1.97	1.85	2.09	12.6	13.4	11.9

Prices as of Aug 3, 2010

Year	2010	2011
Implicit Price	30.74	26.23

Source: BankM Research

Tables

P & L Q1/10 and Quarterly Forecasts 2010

Fiscal Year 31/12 • IFRS	2009a	H1/09a	H1/10a	Delta %	Q3/10e	Q4/10e	2010e
Total Sales	101,399.0	52,353.0	52,884.0	1.0%	27,453.8	27,728.4	108,066.2
Cost of Sales	50,275.0	24,744.0	24,574.0	-0.7%	12,903.3	13,032.3	50,509.6
<i>% of sales</i>	49.6	47.3	46.5		47.0	47.0	46.7%
Gross Profit	51,124.0	27,609.0	28,310.0	2.5%	14,550.5	14,696.0	57,556.6
Distribution Expenses	18,425.0	9,948.0	9,442.0	-5.1%	4,941.7	4,991.1	19,374.8
<i>% of sales</i>	18.2	19.0	17.9		18.0	18.0	17.9
Administrative Expenses	19,083.0	9,509.0	9,253.0	-2.7%	4,667.1	4,713.8	18,634.0
<i>% of sales</i>	18.8	18.2	17.5		17.0	17.0	17.2
R&D Expenses	2,496.0	943.0	1,034.0	9.7%	686.3	831.9	2,552.2
<i>% of sales</i>	2.5	1.8	2.0		2.5	3.0	2.4
Other Operating Income	9,339.0	673.0	1,045.0	55.3%	0.0	0.0	1,045.0
Other Operating Expenses	4,996.0	227.0	248.0	9.3%	0.0	0.0	248.0
Income from Ord. Business	15,463.0	7,655.0	9,378.0	22.5%	4,255.3	4,159.4	17,792.7
Foreign exchange gains/losses	147.0	400.0	638.0	59.5%	0.0	0.0	638.0
Other Financial Items	808.0	-207.0	0.0	n.a.	0.0	0.0	0.0
Financial Result	955.0	193.0	638.0	230.6%	0.0	0.0	638.0
EBIT	16,418.0	7,848.0	10,016.0	27.6%	4,255.3	4,159.4	18,430.7
<i>% of sales</i>	16.2	15.0	18.9		15.5	15.0	17.1
Interest Income	68.0	30.0	123.0	310.0%	60.0	60.0	243.0
Interest Expenses	1,331.0	723.0	718.0	-0.7%	397.0	397.0	1,512.0
EBT	15,155.0	7,155.0	9,421.0	31.7%	3,918.3	3,822.4	17,161.7
Taxes on Income (Exp. -/Inc. +)	6,737.0	-1,344.0	-3,562.0	165.0%	-1,175.5	-1,146.7	-5,884.2
<i>t/o deferred taxes (Exp. -/Inc. +)</i>	11,795.0	-79.0	-360.0		-607.2	-607.2	-1,574.4
Net Profit before Minorities	21,892.0	5,811.0	5,859.0	0.8%	2,742.8	2,675.6	11,277.5
Result from discontinued operations		97.0	0.0		0.0	0.0	0.0
Minorities	8,642.0	1,943.0	732.0	-62.3%	400.0	400.0	1,152.0
Net Profit after minorities	13,250.0	3,965.0	5,127.0	29.3%	2,342.8	2,275.6	9,745.5
<i>% of sales</i>	13.1	7.6	9.7		8.5	8.2	7.8
Adjustments	-5,796.0	0.0	0.0		0.0	0.0	0.0
Adjusted Net Profit	7,454.0	3,965.0	5,127.0	29.3%	2,342.8	2,275.6	9,745.5
<i>% of sales</i>	7.4	7.6	9.7		8.5	8.2	7.8
No. of Shares*	3,783	3,670	5,216		5,260	5,260	5,260
Net Profit/Share (EPS)	3.50	1.08	0.98		0.45	0.43	1.85
Adj. Net Profit/Share (EPS)	1.97	1.08	0.98		0.45	0.43	1.85

Source: BankM Research

BITTE BEACHTEN SIE DIE HINWEISE, ANGABEN UND DEN DISCLAIMER AM ENDE DIESER STUDIE!

Eckert & Ziegler AG

6 August 2010

Tables - 7/11 -

Profit & Loss Account

Fiscal Year 31/12 • IFRS	09a	10e	11e	12e	13e	10e	11e	12e	13e	5y - CAGR
in T€						y-o-y changes (%)				
Total Sales	101,399.0	108,066.2	116,850.1	126,161.2	134,992.4	6.6	8.1	8.0	7.0	13.5
Cost of Sales	50,275.0	50,509.6	54,031.0	57,705.5	61,069.9	0.5	7.0	6.8	5.8	10.3
<i>% of Sales</i>	49.6	46.7%	46.2	45.7	45.2					
Gross Profit	51,124.0	57,556.6	62,819.2	68,455.6	73,922.5	12.6	9.1	9.0	8.0	16.7
Distribution Expenses	18,425.0	19,374.8	20,365.4	21,357.4	22,177.4	5.2	5.1	4.9	3.8	8.0
<i>% of Sales</i>	18.2	17.9	17.4	16.9	16.4					
General & Admin. Expenses	19,083.0	18,634.0	19,564.3	20,492.5	21,252.0	-2.4	5.0	4.7	3.7	7.8
<i>% of Sales</i>	18.8	17.2	16.7	16.2	15.7					
R&D Expenses	2,496.0	2,552.2	3,505.5	3,784.8	4,049.8	2.3	37.4	8.0	7.0	5.4
<i>% of Sales</i>	2.5	2.4	3.0	3.0	3.0					
Other Operating Income	9,339.0	1,045.0	0.0	0.0	0.0					
Other Operating Expenses	4,996.0	248.0	0.0	0.0	0.0					
Income from Ord. Business	15,463.0	17,792.7	19,383.9	22,820.9	26,443.3	15.1	8.9	17.7	15.9	22.5
Foreign exchange gains/losses	147.0	638.0	0.0	0.0	0.0					
Other Financial Items	808.0	0.0	0.0	0.0	0.0					
Financial Result	955.0	638.0	0.0	0.0	0.0					
EBIT	16,418.0	18,430.7	19,383.9	22,820.9	26,443.3	12.3	5.2	17.7	15.9	22.8
<i>% of Sales</i>	16.2	17.1	16.6	18.1	19.6					
Interest Income	68.0	243.0	50.0	50.0	50.0					
Interest Expenses	1,331.0	1,512.0	1,950.0	2,000.0	2,050.0					
EBT	15,155.0	17,161.7	17,483.9	20,870.9	24,443.3	13.2	1.9	19.4	17.1	24.1
Taxes on Income (Exp./Inc.+)	6,737.0	-5,884.2	-5,245.2	-6,261.3	-7,333.0					
<i>1/0 deferred taxes (Exp./Inc.+)</i>	<i>11,795.0</i>	<i>-1,574.4</i>	<i>-1,731.9</i>	<i>-1,905.1</i>	<i>-2,095.6</i>					
Net Profit before minorities	21,892.0	11,277.5	12,238.8	14,609.7	17,110.3	-48.5	8.5	19.4	17.1	41.3
Minorities	8,642.0	1,152.0	1,267.2	1,394.0	1,533.3					
Net Profit	13,250.0	9,745.5	10,971.5	13,215.7	15,577.0	-26.4	12.6	20.5	17.9	28.2
<i>% of Sales</i>	13.1	9.0	9.4	10.5	11.5					
Adjustments	-5,796.0	0.0	0.0	0.0	0.0					
Adjusted Net Profit	7,454.0	9,745.5	10,971.5	13,215.7	15,577.0	30.7	12.6	20.5	17.9	35.2
<i>% of Sales</i>	7.4	9.0	9.4	10.5	11.5					
<i>For Information purposes</i>										
Depreciation & Amortization	11,525.0	5,943.6	6,426.8	6,938.9	7,424.6	-48.4	8.1	8.0	7.0	-4.1
<i>% of Sales</i>	11.4	5.5	5.5	5.5	5.5					
EBITDA	27,943.0	24,374.3	25,810.7	29,759.8	33,867.9	-12.8	5.9	15.3	13.8	12.7
No. of Shares (Ø outstanding)	3,783	5,260	5,260	5,260	5,260	39.0	0.0	0.0	0.0	n.a.
Net Profit/Share (EPS)	3.50	1.85	2.09	2.51	2.96	-47.1	12.6	20.5	17.9	15.6
Adjusted Net Profit/Share (adj. EPS)	1.97	1.85	2.09	2.51	2.96	-6.0	12.6	20.5	17.9	22.0

Source: BankM Research

Cash Flow Statement

Fiscal Year 31/12 • IFRS	09a	10e	11e	12e	13e	10e	11e	12e	13e	5y - CAGR
in T€						y-o-y changes (%)				
Net Profit	21,892.0	11,277.5	12,238.8	14,609.7	17,110.3	-48.5	8.5	19.4	17.1	41.3
+ Depreciation & Amortisation	11,525.0	5,943.6	6,426.8	6,938.9	7,424.6	-48.4	8.1	8.0	7.0	-4.1
+ Chg. in long-term Provisions	-6,821.0	-1,000.0	-1,000.0	-1,000.0	-1,000.0					
= Cash Earnings	26,596.0	16,221.1	17,665.5	20,548.5	23,534.9	-39.0	8.9	16.3	14.5	3.1
- other non-cash items	11,018.0	-1,574.4	-1,731.9	-1,905.1	-2,095.6					
- Chg. in Net Working Capital	-6,534.0	3,529.8	4,107.2	4,398.9	1,990.8					
= Operating Cash Flow	22,112.0	14,265.7	15,290.2	18,054.6	23,639.7	-35.5	7.2	18.1	30.9	22.4
- Capex	9,698.0	30,945.3	9,348.0	10,092.9	10,799.4	219.1	-69.8	8.0	7.0	14.6
= Free Cash Flow	12,414.0	-16,679.6	5,942.1	7,961.7	12,840.3	n.a.	n.a.	34.0	61.3	32.6
+ Net Other Items	476.0	0.0	0.0	0.0	0.0	n.a.	0.0	0.0	0.0	n.a.
- Dividends (Previous Year)	1,132.0	2,335.0	3,118.6	3,291.5	3,964.7	106.3	33.6	5.5	20.5	38.2
- Payout minorities	409.0	449.9	494.9	544.4	598.8					
+ Increase in Share Capital	23,929.0	0.0	0.0	0.0	0.0					
- Outflow from Share Buy Backs	436.0	0.0	0.0	0.0	0.0					
+/- Bank Loans	1,521.0	5,750.0	0.0	0.0	0.0					
= Incr. in Cash (+)/Decr. in Cash (-)	36,363.0	-13,714.5	2,328.7	4,125.9	8,276.7	n.a.	n.a.	77.2	100.6	23.0

Source: BankM Research

BITTE BEACHTEN SIE DIE HINWEISE, ANGABEN UND DEN DISCLAIMER AM ENDE DIESER STUDIE!

Balance Sheet

Fiscal Year 31/12 • IFRS in T€	09a	10e	11e	12e	13e	10e	11e	12e	13e
Assets						% of Balance Sheet Total			
Tangible Assets	27,253.0	30,855.2	34,750.21	38,955.58	43,455.33	20%	22%	23%	24%
Intangible Assets	42,123.0	41,222.4	40,248.7	39,197.4	38,072.4	27%	25%	23%	21%
<i>t/o Goodwill</i>	22,503.0	22,503.0	22,503.0	22,503.0	22,503.0	15%	14%	13%	13%
Deferred Tax	11,795.0	10,220.6	8,488.7	6,583.6	4,488.1	7%	5%	4%	3%
Other Fixed Assets	1,760.0	1,760.0	1,760.0	1,760.0	1,760.0	1%	1%	1%	1%
Total Fixed Assets	82,931.0	84,058.2	85,247.6	86,496.6	87,775.8	55%	54%	52%	49%
Inventories	12,631.0	13,461.5	14,555.7	15,715.6	16,815.6	9%	9%	9%	9%
Accounts Receivable	16,204.0	17,269.4	18,673.2	20,161.1	21,572.4	11%	12%	12%	12%
Total Liquid Funds	43,674.0	29,959.5	32,288.2	36,414.1	44,690.9	20%	20%	22%	25%
Other Current Assets	6,464.0	6,889.0	7,449.0	8,042.5	8,605.5	5%	5%	5%	5%
Total Current Assets	78,973.0	67,579.5	72,966.1	80,333.3	91,684.4	45%	46%	48%	51%
Balance Sheet Total	161,904.0	151,637.7	158,213.7	166,829.9	179,460.2	100%	100%	100%	100%
Liabilities						% of Balance Sheet Total			
Subscribed Capital	5,260.0	5,260.0	5,260.0	5,260.0	5,260.0	3%	3%	3%	3%
Share Premium	52,719.0	52,719.0	52,719.0	52,719.0	52,719.0	35%	33%	32%	29%
Retained Earnings & Other Reserves	18,426.0	8,536.5	16,389.5	26,313.7	37,926.0	6%	10%	16%	21%
Shareholders Equity	76,405.0	66,515.5	74,368.5	84,292.7	95,905.0	44%	47%	51%	53%
Minorities	10,254.0	6,054.0	7,321.3	8,715.2	10,248.6	4%	5%	5%	6%
Group Equity	86,659.0	72,569.5	81,689.7	93,007.9	106,153.5	48%	52%	56%	59%
Provisions	23,296.0	22,296.0	21,296.0	20,296.0	19,296.0	15%	13%	12%	11%
<i>t/o Pension Provisions</i>	5,707.0	6,082.2	6,576.6	7,100.7	7,597.7	4%	4%	4%	4%
Other Liabilities	51,949.0	56,772.2	55,228.0	53,526.0	54,010.7	37%	35%	32%	30%
Total Liabilities	75,245.0	79,068.2	76,524.0	73,822.0	73,306.7	52%	48%	44%	41%
<i>t/o LT Liabilities</i>	41,247.0	42,834.8	37,345.4	31,521.5	28,045.2	28%	24%	19%	16%
<i>t/o ST Liab. <1Y</i>	33,998.0	36,233.4	39,178.6	42,300.5	45,261.5	24%	25%	25%	25%
<i>t/o Acc Payable & Adv. Paymts.</i>	12,431.0	10,797.1	9,187.8	7,436.7	7,957.2	7%	6%	4%	4%
Balance Sheet Total	161,904.0	151,637.7	158,213.7	166,829.9	179,460.2	100%	100%	100%	100%

Source: BankM Research

BITTE BEACHTEN SIE DIE HINWEISE, ANGABEN UND DEN DISCLAIMER AM ENDE DIESER STUDIE!

Important information, disclosures and disclaimer

A. Important information

Equity investments generally involve high risks. Investors may lose some or all of the money invested. Potential investors should take into account that share prices may fall and rise and that income from an investment may fluctuate considerably. Past performance is no guarantee for future results. Investors make their decisions at their own risk.

B. Disclosures according to Section 34b of the German Securities Trading Act (WpHG) and the Ordinance on the Analysis of Financial Instruments (FinAnV):

I. Information about author, company held accountable, regulatory authority:

Responsible for the content of this document: biw Bank für Investments und Wertpapiere AG, Willich, Germany.

Author: Dr. Roger Becker, CEFA, Biologist

Regulatory authority for biw Bank für Investments und Wertpapiere AG is the Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin), Graurheindorfer Straße 108, 53117 Bonn, Germany and Lurgiallee 12, 60439 Frankfurt am Main, Germany.

Issuer of the analyzed instrument is Eckert & Ziegler AG.

Notice according to sec. 4 §. 4 N° 4 FinAnV (previous publications regarding the issuer at least within the last 12 months):

Analyst	Date	Evaluation result	Fair value
Dr. Roger Becker	April 1, 2009	Buy	€10.56
Dr. Roger Becker	May 5, 2009	Buy	€10.56
Dr. Roger Becker	July 10, 2009	Buy	€14.50
Dr. Roger Becker	August 7, 2009	Neutral	€19.26
Dr. Roger Becker	November 4, 2009	Buy	€22,21
Dr. Roger Becker	November 16, 2009	Buy	€22,90
Dr. Roger Becker	December 17, 2009	Buy	€22,90
Dr. Roger Becker	January 29, 2010	Buy	€24.00
Dr. Roger Becker	March 25, 2010	Neutral	€24.00
Dr. Roger Becker	April 12, 2010	Buy	€27.44
Dr. Roger Becker	May 10, 2010	Buy	€28.22

II. Additional Information:

1. Sources of information:

Main sources of information for the compilation of this document are publications in national and international media and information services (e.g. Reuters, VWD, Bloomberg, dpa-AFX and others), financial newspapers and magazines (e.g. Börsenzeitung, Handelsblatt, Frankfurter Allgemeine Zeitung, Financial Times and others), specialist media, published statistics, rating agencies as well as publications by peer group companies and the company itself. Furthermore talks with the management of the issuer have been held. This document was made available to the issuer before publication to ensure the accuracy of the information provided. This resulted in no textual changes.

2. Summary of the valuation principles and methods used to prepare this document:

BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG uses a 3-tier absolute rating model. The ratings are the evaluation results and refer to a fair value pricing reflecting a time-horizon of up to 12 months.

BUY: The calculated fair value of the company's stock is at least 15 % higher than the current market price at the time of the compilation of this document.

NEUTRAL: The calculated fair value of the company's stock lies between -15% and +15 % of the current market price at the time of the compilation of this document.

SELL: The calculated fair value of the company's stock is at least 15 % lower than the current market price at the time of the compilation of this document.

The following valuation methods are being used: Multiple-based models (Price/Earnings, Price/Cash-flow, Price/Book value, EV/Sales, EV/EBIT, EV/EBITA, EV/EBITDA), peer-group comparisons, historical valuation approaches, discount models (DCF, DDM), break-up value and sum-of-the-parts-approaches, asset-based evaluation methods or a combination of the above. The used valuation models depend on macroeconomic factors, such as interest rates, exchange rates, raw materials and on basic assumptions about the economy. Additionally, market sentiment affects the valuation of companies. The valuation is also based on expectations that might change rapidly and without notice, depending on developments specific to individual industries. Rendered evaluation results and fair values derived from the models might therefore change respectively. The evaluation results in general relate to a 12-month horizon. However, evaluation results are subject to changing market conditions and represent only the situation at a given point of time. The evaluation results and fair value prices may in fact be achieved more quickly or slowly than expected by the analysts. Also, the evaluation results and fair value prices might need to be revised upward or downward.

3. Date of first publication of this document:

August 6, 2010

4. Date and time of prices of the instruments quoted in this document:

Closing prices of August 4, 2010

5. Updates:

A specific date or time for an update of this document has not been set. The information given in this document reflects the author's judgement on the date of this publication and is subject to change without notice; it may be incomplete or condensed and it may not contain all material information concerning the company covered. It is in the sole responsibility of BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG to decide on a potential update of this document.

III. Disclosures about potential conflicts of interest:

1. BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG's business model is based on economic relationships with issuers and equity transactions to be performed relating to the issuer's stock. BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG has entered into an agreement about the preparation of this document with the issuer that is, or whose financial instruments are, the subject of this document.

BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG was mandated as sole lead manager and sole bookrunner for the rights issues of Eckert & Ziegler AG conducted in January/February 2009 and November/December 2009 and, in this connection, has been party to an agreement on the provision of investment banking services with the issuer that is, or whose financial instruments are, the subject of this document.

Moreover, BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG was party to an other agreement on the provision of investment banking services with the issuer that is, or whose financial instruments are, the subject of this document.

BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG (incl. subsidiaries and affiliates), the authors of this document as well as other persons that were involved in the compilation of this document or affiliated parties:

- **do not have a major shareholding (shareholding exceeding 5%) of the share capital of the issuer that is, or whose financial instruments are, the subject of the analysis. Board members, directors, employees or clients of biw Bank für Investments und Wertpapiere AG possibly are holders of instruments that are mentioned in this document (or that are related to these instruments) or could become holders and could regularly trade the issuer's securities or securities based on these issues as principal or agent,**
- **have no other significant economic interests relating to the issuer that is, or whose financial instruments are, the subject of this analysis.**

2. In the function as a designated sponsor, BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG manages the financial instruments that are, or whose issuers are, the subject of the financial analysis on a market by placing buy or sell orders and will regularly hold a trading stock or long or short positions in the issuer's stock.

3. BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG's internal organisation is aligned with the prevention of conflict of interests in producing and distributing research reports. Possible conflicts of interests will be treated adequately. In particular, physical and non-physical boundaries were installed to keep analysts from gaining access to information that possibly could constitute a conflict of interest for the bank. biw Bank für Investments und Wertpapiere AG keeps insider registers according to sec. 15 WpHG for employees and assignees that normally have access to inside information. These registers will be transmitted to BaFin on request. Insiders' dealings according to sec. 14 WpHG categorically are prohibited. Staff members that fill a specific position and have access to inside information categorically have to disclose all dealings in financial instruments to the internal compliance department. The compliance of legal requirements and supervisory regulations is subject to continuous supervision and control of the compliance department of biw Bank für Investments und Wertpapiere AG. In this regard, the right to restrict employees' dealings in financial instruments is reserved.

4. The remuneration of the analysts mentioned above is not dependent on any investment banking transactions of BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG or its affiliates. The analysts that compiled this document did not receive or acquire shares in the issuer that is, or whose financial instruments are, the subject of this document at any time. The analysts mentioned above hereby certify that all of the views expressed accurately reflect his or her personal views about the issuer and that no part of his or her compensation was, is or will be, directly or indirectly, related to the specific evaluation result or views expressed by the analyst in this document.

5. Updated information according to sec. 5 para. 4 N^o. 3 FinAnV is available at: http://www.bankm.de/webdyn/138_cs_Gesetzliche+Angaben.html.

C. Disclaimer:

This document was compiled by BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG solely for informational purposes and for the personal use by persons in Germany that are interested in the company and who purchase or sell transferable securities for their own account or the account of others in the context of their trade, profession or occupation. This document neither constitutes a contract nor any kind of obligation.

This document and its content, in whole or in part, may not be reproduced, distributed, published or passed on to any other person without the prior written consent of BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG.

This publication is for distribution in or from the United Kingdom only with the prior written consent of BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG and only to persons who are authorised persons or exempted persons within the meaning of the Financial Services and Markets Act 2000 of the United Kingdom or any order made there under or to investment professionals as defined in Section 19(5) of the Financial Services and Markets Act 2000 (financial promotion) order 2005 (the order) respectively in the version as amended from time to time and is not intended to be distributed or passed on, directly or indirectly, to any other class of persons.

Neither this document nor any copy of it may be taken or transmitted into the United States of America, Canada, Japan or Australia or distributed, directly or indirectly, in the United States of America, Canada, Japan or Australia or to any resident thereof.

The distribution of this document in other jurisdictions may be restricted by law, and persons who are in possession of this document have to inform themselves about any such restrictions and observe any such restrictions.

This document is not intended to be an offer, or the solicitation of any offer, or any advice or recommendation to buy or sell the securities referred to herein. This document is intended to provide information to assist institutional investors in making their own investment decisions, not to provide investment advice to any specific investor. Potential investors should seek professional and individual advice before making their investment decisions. Investment decisions must not be based on this document.

The information within this document has been obtained from sources believed by BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG to be reliable, but BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG does not examine the information to be accurate and complete, nor guarantees its accuracy and completeness. Although due care has been taken in compiling this document, it cannot be excluded that the information given is incomplete or the document contains errors. The liability of BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG shall be restricted to gross negligence and wilful misconduct. All opinions expressed in this document are those of BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG respectively the authors and subject to change without notice. Possible errors or incompleteness of this document may be corrected by BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG and do not constitute grounds for liability, neither with regard to indirect nor to direct or consequential damages. Only in case of failure in essential tasks, BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG is liable for simple negligence. In addition BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG does not accept any liability or responsibility for any loss arising from any use of this publication or its contents or otherwise arising in connection herewith.

BITTE BEACHTEN SIE DIE HINWEISE, ANGABEN UND DEN DISCLAIMER AM ENDE DIESER STUDIE!

Eckert & Ziegler AG

6 August 2010

Important information, disclosures and disclaimer - 11/11 -

In any case, the liability of BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG is limited to typical, foreseeable damages and the liability for any indirect damages is excluded.

By accepting this document, the reader/user of this document agrees to be bound by all of the foregoing provisions and this disclaimer. Moreover, the user agrees not to distribute this document to unauthorized persons. The user of this document shall indemnify BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG for any damages, claims, losses, and detriments resulting from or in connection with the unauthorized use of this document.

This document is subject to the laws of the Federal Republic of Germany. Place of jurisdiction is Frankfurt am Main, Germany.

Should certain specifications of this disclaimer not be legally binding or become legally non-binding, this will have no impact on the legally binding character of this disclaimer and its other legal specifications.

This document is not intended for use by persons resident in any jurisdiction that regulates access to such documents by applicable laws. Investment decisions must not be based on any statement in this document. Persons in possession of this document should inform themselves about possible legal restrictions and observe them accordingly. In case of uncertainty persons should not access and/or consider the content of this document in any decisions. This document is not intended for use by persons that are classified as US-persons under the United States Securities Act.

© 2010 BankM - Repräsentanz der biw Bank für Investments und Wertpapiere AG, Mainzer Landstraße 61, D-60329 Frankfurt.

biw Bank für Investments und Wertpapiere AG, Hausbroicher Straße 222, D-47877 Willich. All rights reserved.

This document is a translation of the legally binding German original version of August 6, 2010.

BITTE BEACHTEN SIE DIE HINWEISE, ANGABEN UND DEN DISCLAIMER AM ENDE DIESER STUDIE!